Condition
Medullary Thyroid Cancer (MTC)
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed3
Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07142005RecruitingPrimary
Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer
NCT07048964Not Yet RecruitingPrimary
A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
NCT01856920Phase 2CompletedPrimary
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
NCT03072160Phase 2CompletedPrimary
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
NCT01788982Phase 2CompletedPrimary
Nintedanib(BIBF1120) in Thyroid Cancer
Showing all 5 trials